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Objectives: Prolonged exposure to CNI-based immunosuppressant therapy (IS) 
in liver transplant (LTx) recipients is associated with long-term complications. 
In the global registration trial H2304, patients receiving everolimus + reduced 
tacrolimus (EVR + reduced TAC) demonstrated non-inferior efficacy and supe-
rior renal function at Month 12 that was sustained at 36 months compared to 
tacrolimus alone (TAC). A peer-reviewed Markov model has been adapted to the 
Italian setting to explore the cost-effectiveness of EVR + reduced TAC compared to 
TAC, in de novo liver-recipients. MethOds: The model estimates long-term out-
comes associated with IS following LTx along two independent pathways: 1. liver-
related (acute rejection, hepatocellular carcinoma, hepatitis C [HCV] recurrence, 
graft loss); 2. kidney-related (chronic kidney disease, dialysis, renal transplanta-
tion) and death. All patients, stratified by liver diagnosis, entered the model at time 
of LTx and followed both pathways, allowing for multiple combinations of liver 
and kidney health states. The lifetime model used an annual cycle length 
except for the 1styear post LTx (quarterly). Efficacy and safety of IS strategies 
were assessed through the risk of acute rejection, change in renal function, HCV 
fibrosis progression and frequency of adverse events. Utilities and costs were 
assigned to each renal and liver state. Subgroup and sensitivity analyses were 
performed. Results: With a mean life expectancy of 18 years, the model predicts 
patients treated with EVR + reduced TAC gain on average 1.84 years of life and 1.55 
QALYs vs. TAC. The risk of acute rejection was reduced by 20%. The incremental 
cost of EVR + TAC was € 38,884 per life year gained and € 46,103 per QALY gained 
vs. TAC. cOnclusiOns: This model shows a strategy of EVR + reduced TAC post- 
LTx improves survival and quality of life. Higher treatment costs are offset by 
slower progression of renal deterioration predicted in the first 10 years and fewer 
lifetime liver complications.
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Objectives: Nonalcoholic fatty liver disease (NAFLD) is the most common liver 
condition in Western countries. To date, no studies have examined the cost-
effectiveness of screening for nonalcoholic steatohepatitis (NASH), its advanced 
form. MethOds: We performed a cost-utility analysis of annual non-invasive 
screening strategies using a third-party payer perspective in a general population 
and compared it to screening in a high-risk obese or diabetic population. Screening 
algorithms involved well-studied non-invasive techniques including NAFLD fibro-
sis score, ultrasound transient elastography (TE), and ultrasound acoustic radiation 
force impulse (ARFI) imaging for detecting advanced fibrosis (≥ F3); and plasma 
cytokeratin-18 for NASH detection. Liver biopsy and magnetic resonance elas-
tography (MRE) were compared as confirmation methods. Model uncertainties 
were tested using sensitivity analyses. Canadian dollar costs were adjusted for 
inflation and discounted at 5%. Incremental cost-effectiveness ratio (ICER) of 
$C50,000 per quality-adjusted life year (QALY) or less was considered cost-effec-
tive. Results: Compared with no screening, screening with NAFLD fibrosis score/
TE/CK-18 algorithm with MRE as confirmation for advanced fibrosis had an ICER 
of $C26,143 per QALY gained. Screening in high-risk obese or diabetic populations 
was more cost-effective, with an ICER of $C9,051 and $C7,991 per QALY gained 
respectively. Screening algorithms with liver biopsy confirmation were not found 
to be cost-effective. Sensitivity analyses revealed that the screening starting age, 
the annual transition probability from simple steatosis to NASH, and the cost of 
a TE exam had the most impact on the results. cOnclusiOns: Our model sug-
gests that annual NASH screening in high-risk obese or diabetic populations can 
be cost-effective.
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Objectives: Sofosbuvir in combination with ribavirin (SOF/RBV) is a novel treat-
ment able to suppress HCV viremia when applied to HCV patients listed for 
transplant, preventing HCV recurrence. Aim of this study was to assess the cost-
effectiveness of this regimen in HCV patients listed for transplant for cirrhosis (HCV-
cirrhosis) or for hepatocellular carcinoma (HCV-HCC). MethOds: a semi-Markov 
model was developed. The model simulates the progression of HCV-cirrhosis or 
HCV-HCC patients from the time of listing until death considering the risk of HCV 
recurrence post-transplant. The model compared 2 different strategies: 1) SOF/RBV 
up to a maximum of 24 weeks or until OLT if performed before the 24th week, 2) 
No antiviral treatment. The model estimated the costs related to the treatment 
with SOF/RBV, the costs associated to each health state, the life-years (LYSs), the 
quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio 
(ICER) expressed as € per QALY gained. The analysis was performed from the Italian 
National Health System perspective with a lifetime time horizon and one-month 
Markov cycles. Future costs and clinical benefits, expressed as QALYs, were dis-
counted at 3% per year. Results: in the base-case analysis the ICER for 24 weeks 
of SOF/RBVR was € 30,518 per QALY gained in HCV-cirrhosis patients and € 41,610 
in HCV-HCC patients. The reliability of our results was confirmed by the one way 
sensitivity-analysis and by the cost-effectiveness acceptability curve. Further, SOF/
RBV cost-effectiveness was clearly sensitive to the duration of treatment; assum-
ing 12 weeks SOF/RBV treatment duration, the ICER decreased to € 19,317 in HCV-
Cirrhosis and € 29,540 in HCV-HCC. cOnclusiOns: our study shows that treating 
patients with HCV-cirrhosis or HCV-HCC listed for transplant with SOF/RBV is cost-
effective and may become the new standard of care for these patients. However a 
well-defined prospective study is needed to confirm the value of the parameters 
assumed in the model and the results.
LY was calculated. Sensitivity analyses were performed. Results: Model results for 
treatment-experienced patients show that SMV is the dominant treatment com-
pared to TVR+PR and BOC+PR therapies as more total LYs are saved and less costs 
accrued. ICER of SMV+PR vs PR was € 22,967 per LY. Results were robust in sensitivity 
analyses. cOnclusiOns: SMV + PR is cost-effective compared to dual PR-therapy 
and appears the dominant strategy compared to other PI (telaprevir, boceprevir) for 
CHC treatment-experienced patients in Russia.
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Objectives: Studies based on the data of clinical trials have proved that the triple 
therapy for hepatitis C is cost effective. This study we assessed the cost-effective-
ness of triple therapy in treatment of Chronic Hepatitis C with Severe Fibrosis under 
“real-life” conditions. MethOds: The analysis was conducted from the data included 
in the prospective, multicentre, Spanish registry that includes patients with HCV-
genotype-1 infection, who had severe fibrosis and were treated with triple therapy 
(peginterferon alfa-2a or 2b, ribavirin, and boceprevir). The cost effectiveness analysis 
of antiviral treatment includes the costs of antiviral treatment, of concomitant treat-
ments and costs in relation to health care resources (in relation to clinical practice 
and the adverse events). Results: 170 patients were included. 68.2% male, mean 
age of 53 (29-76) years. 80% had received prior treatment. 36.5% of patients reported 
at least one SAEs. The overall percentage of patients with SVRw12 was 46.5%. The 
cost of triple therapy represented a total of 4,916,652.84€ , the pharmacological cost 
(triple therapy+concomitant treatment) involved a total cost of 5,161,168.98€ . The 
consumption of health resources generated an additional cost of 240,000 € , which is 
about 1,500€ /patient. The total cost per patient cured was 70,262€ . This cost varies 
greatly based on different baseline characteristics of the patients, with significant 
differences in patients with albumin < 3.5, 120,597€ ; prior null response 120,727€ and 
platelets < 90,000,104,464€ . cOnclusiOns: The current scenario of the hepatitis C 
treatment is changing. Triple therapy is more costly for patients with severe fibrosis 
and predictors of poor response. However, keeping in mind that the timeframe for the 
release of IFN-free regimens remains uncertain and considered that the actual access 
to the new DAA in the real world setting could be delayed, boceprevir could remain 
as an option for patients with intact liver function and a high unmet medical need, 
regardless of the degree of liver fibrosis, in locations where a delay in the access to 
the newer therapies is foreseen and hepatic transplant would not be readily available.
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Objectives: The aim of this study is to compare the cost effectiveness of oral anti-
viral treatment strategies in CHB for Turkey using lamuvidine, telbuvidine, entecavir, 
and tenofovir as medications. MethOds: The analysis was conducted using Markov 
model. Inadequate response or resistance after receiving 12 months of the treatment 
with entecavir and telbivudine were compared to the results found from switching 
from entecavir to tenofovir or from switching from telbuvidine to tenofovir. In addi-
tional, inadequate response or resistance after receiving 6 months of the treatment 
for lamivudine was compared to the results found from switching from lamivudine 
to tenofovir. The model duration was constructed to evaluate a treatment strategy 
duration of 40 years. Years of Potential Life Lost (YPLL) was used as the health 
outcome. An incremental cost-effectiveness ratio (ICER) analysis of the results was 
conducted. Results: In a life time period, the lowest YPLL and the cost of treatment 
were calculated for the NS. Tenofovir treatment with 0.54 years and 37,213.75 TL. 
Depending on the results, the lowest YPLL and the cost of treatment were served 
by NS. Tenofovir treatment with 2.06 years and 276,468.45 TL. The highest YPLL and 
the cost of treatment were calculated for the NS. The ICER analysis found that all 
treatment strategies were dominated by NS. Tenofovir and S. Entecavir. Only these 
two treatment strategies were found to be cost-effective. cOnclusiOns: The cost 
of providing 40 years of treatment for patients with CHB, if reimbursement agen-
cies includes Tenofovir and Entecavir as part of the first line treatment strategy for 
CHB, it can be expected that this approach would result in a positive contribution 
to the health budget in Turkey.
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